Sigyn CardioDialysis™ aims to reduce the circulating presence of inflammatory molecules and cholesterol-transporting lipoproteins that increase Major Adverse Cardiovascular Events (MACE).
Our CompanyCardiovascular disease is the leading cause of death globally. The annual market for MACE reduction therapies is estimated to be ~$100 billion.
To support potential broad-scale commercialization, CardioDialysis™ can be conveniently deployed on dialysis machines located at more than 7,500 U.S. dialysis clinics.
"We create medical technologies with two attributes in mind: they must offer to overcome a clearly-defined therapeutic limitation and if demonstrated to be effective, would provide a strategic competitive advantage within an established industry."
Jim Joyce
Chairman and CEO Inventor
Stay informed and receive company updates straight to your inbox.
